Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Follitropin is a recombinant form of human follicle-stimulating hormone (FSH), a glycoprotein hormone produced by the pituitary gland. It acts as an agonist at the follicle-stimulating hormone receptor, stimulating ovarian follicular growth in women and spermatogenesis in men. In clinical practice, it is primarily used to treat infertility—specifically to induce ovulation in women with ovulatory dysfunction and to stimulate multiple follicular development for assisted reproductive technologies such as IVF. In men with hypogonadotropic hypogonadism, it is used to induce sperm production, typically after pretreatment with human chorionic gonadotropin (hCG). Follitropin is administered via subcutaneous injection and may be combined with other hormones depending on the fertility protocol[1][2][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on follitropin.